Moolec Science S.A. (MLEC) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Moolec Science SA (MLEC) 3-Minute Overview > **💡 One-Sentence Summary** > > Moolec is a tiny, early-stage “food-tech” company that bio-engineers plants to produce animal-like proteins and specialty oils, aiming to sell high-value ingredients to the food industry. > **📍 Basic Profile** > > Market Cap **~$12.4 million** · Food Products / Food-Tech · NASDAQ · Price **$17.10** --- > **⚡ 3 Things You Should Know** > > 1. 🔬 **Story stock, not earnings stock yet:** Moolec is still deeply loss-making (net margin about **-106%**, ROE around **-151%**). The attraction here is the technology and future potential, not current profits or cash generation. > > 2. ⚠️ **Financial risk is real:** Leverage is high (debt-to-equity **>2x**), liquidity is only okay (current ratio ~1.5, quick ratio <1), and cash flow per share is sharply negative. In plain English: they’re burning cash, leaning on debt, and will likely need more funding if the business doesn’t ramp up quickly. > > 3. 🎢 **Extreme volatility and event-driven moves:** The stock swung from a **52-week low of $3.08 to a high of $157+**, and recently spiked after promising GLA (gamma‑linolenic acid) data and a **15‑for‑1 reverse split**. This trades more like a high-risk biotech/food-tech lottery ticket than a stable food company. --- > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |------------------|----------------------------|---------| > | Profitability | Weak👎 | Net margin ~**-106%**, negative gross and operating margins | > | Growth Rate | [Data unavailable] | Revenue/growth not provided; clearly not at scale yet | > | Financial Health | Tight🧡 | Debt-to-equity **~2.15**, quick ratio **<1**, negative cash flow per share | > | Valuation | Speculative / Story-driven | No PE (loss-making); PS ~**1.6x**, PB ~**7x** for a pre-profit micro-cap | --- ## 📋 Layer 2: 2-Minute Deep Dive ### 📊 How Does This Company Make Money? **Business Model in One Sentence:** Moolec engineers plants and microbes to produce animal proteins and nutritional oils, then aims to sell these as functional ingredients (like specialty oils with high GLA content) to food and nutrition companies. **Revenue Breakdown:** (Exact breakdown not available; business is still early-stage and not at meaningful scale.) | Business | Share | Trend | Comment | |----------|-------|-------|---------| | Plant-produced proteins & oils | [Data unavailable] | ↑ (pipeline news-driven) | Core R&D and early commercial pilots like GLASO1 high‑GLA oil | | Other/Services/Grants | [Data unavailable] | [Data unavailable] | Likely small; no detailed data shown | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |---------------|-------------:|------------------|----------------| | Gross Margin | **-8.2%** | Well below avg | Even at gross level they’re losing money – production still inefficient and/or small scale. | | Net Margin | **-105.7%** | Bottom tier | For every $1 in sales, they lose about $1+; classic early-stage deep-loss profile. | | ROE | **-150.9%** | Extremely weak | Equity base is tiny vs. losses; reflects aggressive burn vs. capital. | In other words, this is a **R&D-heavy platform** company that has not yet converted technology into profitable scale. --- ### 📈 How’s the Growth? **Growth Assessment:** [Revenue growth data unavailable] – but fundamentals suggest the company is **pre-scale**, focused on proving technology and starting commercialization (e.g., GLASO1 GLA oil). We do have **EPS trend vs. expectations**: | Period (FY 2024) | EPS Actual | EPS Estimate | Surprise | Trend | |------------------|-----------:|------------:|---------:|-------| | 2024-12-31 | -9.00 | -9.18 | +0.18 | Slight beat, still very negative | | 2024-09-30 | -7.50 | -10.71 | +3.21 | Large beat (loss narrower than feared) | | 2024-06-30 | -10.50 | -9.18 | -1.32 | Miss (loss worse than expected) | | 2024-03-31 | -0.40 | -0.71 | +0.31 | Beat, but quarterly swings are huge | **Growth Quality:** What’s happening is less about “growth” and more about **burn pattern**: - Losses bounce around depending on R&D, pilot-scale and one-off items. - No sign yet of operating leverage or a stable revenue base. - Positive surprises mean they’re losing less than expected, not that they’re suddenly profitable. So if you buy this, you’re essentially betting that **today’s heavy R&D and tiny revenues will turn into high-margin ingredient sales later.** --- ### 💰 Financial Health Check **One Sentence:** The balance sheet looks like a household with a startup: modest assets, **lots of debt relative to equity**, negative cash flow, and just enough short-term liquidity to get by for now. | Metric | Value | Safe Zone | Assessment | |---------------------|---------:|------------|------------| | Debt-to-Equity | **2.15** | <0.6 ideal | ⚠️High – balance sheet is quite leveraged for a pre-profit company. | | Long-term D/E | **1.72** | <0.5 ideal | ⚠️High – a big chunk of debt is long-term. | | Current Ratio | **1.48** | >1.5 | ⚠️Tight – just around “okay”, no big buffer. | | Quick Ratio | **0.84** | >1.0 | ⚠️Tight – without inventory, coverage of short-term liabilities is weak. | | Interest Coverage | **-2.13**| >3 | 🚨Negative – can’t cover interest from operating profit. | | Cash Flow/Share TTM | **-1.55**| >0 | 🚨Negative – burning cash, not generating it. | This combination (high leverage, negative margins, negative cash flow) means **financing risk** is a key issue: dilution, refinancing, or even survival can become talking points if commercialization lags. --- ### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: **$3.08** - 52-Week High: **$157.05** - Current: **$17.10** Position within range: Approximate position = (17.1 – 3.08) / (157.05 – 3.08) ≈ **9% from the low, far below the high** So price is **near the low zone** of an extremely wide range, after what was likely a huge speculative spike and comedown. | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0–33% | 33–66% | 66–100% | | **Current** | ●(~9%) | | | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |----------------|----------------------|------------------------|------------| | PE | N/A (loss-making) | N/A | Classic “no-PE” story stock. | | PS (TTM) | **~1.6x** | Many early food-tech: 2–10x+ | PS doesn’t look crazy by sector standards, but revenue base is likely tiny and volatile. | | PB | **~7.0x** | Food products often <3x | High price vs. book, especially for a company without proven profitability. | **What the Current Valuation is Betting On:** - The market is implicitly betting that **Moolec’s tech (like GLASO1 with ~45% GLA)** can become a **commercially valuable platform**. - With no earnings and small revenues, even at a “low” price within its range, the valuation is basically a **speculation on future adoption and IP value**, not on current cash flows. - The recent **reverse split (15:1)** hints that management is trying to **maintain NASDAQ listing and appeal to institutions**, which can be a double-edged sword: often a red flag in micro-caps but also sometimes a reset. --- ### 📰 Any Recent News? | Date (approx) | Event | Impact | |---------------|-------|--------| | 2026-??-?? | “Moolec Science (MLEC) Stock Explodes 90% After GLA Update” | **Positive / Volatile** – Commercial-scale data confirming strong GLA content (GLASO1) boosts the “tech is working” narrative and drives a big speculative spike. | | 2026-??-?? | Subsidiary confirms ~45% GLA concentration in GLASO1 crushing process | **Positive** – Validates that plants can produce high-value nutritional oils at scale, potentially supporting future revenue and partnerships. | | 2025-12-31 | Announces 15-for-1 share consolidation | **Mixed / Caution** – Helps keep share price above listing thresholds, but reverse splits in micro-caps often come when stocks have been beaten down. | | Multiple dates | Featured as top mover / unusual volume | **Sentiment-driven** – Tells you trading is dominated by short-term momentum and speculators, not long-term fundamentals. | --- ## 📊 Layer 3: 3-Minute Complete Analysis ### I. Detailed Financial Data *(Historical year-by-year margins aren’t provided, so we focus on latest TTM)* **Profitability Snapshot:** | Metric | This Year (TTM) | 3-Year Trend | Comment | |---------------|----------------:|--------------|---------| | Gross Margin | **-8.16%** | [N/A] | Negative even before overhead – product economics not yet proven at scale. | | Net Margin | **-105.71%** | [N/A] | Deep losses consistent with a development-stage company. | | ROE | **-150.93%** | [N/A] | Losses dwarf equity; any additional write-downs or dilution will move this a lot. | **Growth Trends (EPS Surprises):** | Quarter End | EPS Actual | EPS Estimate | Surprise | Interpretation | |---------------|-----------:|------------:|---------:|----------------| | 2024-12-31 | -9.00 | -9.18 | +0.18 | Slight beat, but still a huge loss. | | 2024-09-30 | -7.50 | -10.71 | +3.21 | Better than feared; maybe some cost control or timing effects. | | 2024-06-30 | -10.50 | -9.18 | -1.32 | Worse loss; possibly heavier R&D or one-offs. | | 2024-03-31 | -0.40 | -0.71 | +0.31 | Tiny relative loss; quarter-to-quarter volatility is large. | **Earnings Trend Interpretation:** Analysts’ models are clearly **rough estimates** – the business is too small and lumpy to forecast cleanly. Repeated beats here don’t mean “strong performance” in the usual sense; they just mean **losing less than expected** in some quarters. --- ### II. Earnings Track Record (Last 4 Quarters vs Expectations) | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | 2024 Q4 | -9.18 | -9.00 | +1.96% 😀 | | 2024 Q3 | -10.71 | -7.50 | +29.97% 😀 | | 2024 Q2 | -9.18 | -10.50 | -14.38% 😟 | | 2024 Q1 | -0.71 | -0.40 | +43.98% 😀 | **Interpretation:** - Mixed but **more beats than misses**, which keeps analysts moderately optimistic (you can see that in the recommendation mix). - However, **all four quarters are negative**; there’s no evidence yet of approaching profitability. --- ### III. What the Market Thinks **Analyst Ratings (latest available period 2025-07-01):** | Rating | Count | Percentage (of 7) | |-----------------|------:|------------------:| | Strong Buy/Buy | 6 | ~85.7% | | Hold | 1 | ~14.3% | | Sell/Strong Sell| 0 | 0% | So the analyst community **covering** the stock is quite bullish, but remember: - For a micro-cap like this, coverage may be from **smaller firms / specialized boutiques**; - These ratings are **highly dependent on the success of just a few projects** (like GLASO1 and other plant-based proteins). **Target Price:** Exact target range not given in the data, but with that many Buys, the implied view is **meaningful upside** from current levels. The risk is that small-cap targets can be optimistic and thinly researched. **Insider Activity:** No recent insider transactions reported in the dataset. Lack of data doesn’t mean there were none; but we **can’t** read insider conviction here either way. > Generally, insider **buying** in a micro-cap like this would be a strong positive signal; insider **selling** would be more neutral (people diversifying after a spike) unless it’s large and persistent. --- ### IV. Key Risk Alerts 1. **Financing / Dilution Risk:** - **What:** High leverage (D/E >2), negative cash flow, and no profits. Future R&D and commercialization will require capital. - **So what:** If the share price falls or credit conditions tighten, Moolec may have to issue more equity at low prices or take on expensive financing, **diluting existing shareholders** or straining the balance sheet. 2. **Execution & Technology Risk:** - **What:** The core bet is that plants can reliably produce high-value proteins and oils (like GLASO1 with ~45% GLA) at industrial scale and acceptable cost. - **So what:** If yields drop at scale, regulatory approvals lag, or customers don’t adopt, the business case breaks. Years of R&D could translate into **little commercial traction**, leaving only IP with uncertain value. 3. **Market & Volatility Risk:** - **What:** Huge price swings (3 → 157 → 17), reverse split, and frequent “top mover” headlines show the stock is **speculator-driven**. - **So what:** You can see dramatic swings on news, sentiment, or even social media. That’s great for traders but tough for long-term holders; **you can be right about the technology and still lose money** if you buy during a hype spike. --- ## 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** Moolec is a micro-cap food-tech company trying to use plant and microbial engineering to create high-value animal-like proteins and oils, now getting attention for high-GLA oil results. > **Key strength:** If the technology scales (as early GLASO1 data suggests), Moolec could carve out a niche supplying specialized ingredients with attractive pricing power, which is what keeps analysts bullish despite the losses. > **Key risk:** The company is still deeply unprofitable, highly leveraged, and trades with extreme volatility, so the main risk is that commercialization takes too long or under-delivers, forcing dilutive financing and painful price drawdowns. --- > **🔍 Want to Learn More?** > > • Want to know if Moolec has a real moat (IP, switching costs, customer lock-in)? → Try **【Buffett Mode】** for a deeper competitive-advantage dive. > • Want to stress-test bankruptcy/dilution scenarios and governance red flags? → Try **【Muddy Mode】** for detailed risk screening. > • Thinking of this as a high-risk/high-reward growth bet and want to model possible outcomes? → Try **【Musk Mode】** for scenario and valuation analysis.